ClinicalTrials.gg
Active, not recruitingNCT06724926Updated May 18, 2026

Concurrent Azeliragon With Craniospinal Irradiation

A Phase 1 interventional study of Azeliragon and CSI in Solid Tumor, High-grade Glioma and Leptomeningeal Metastasis, sponsored by NYU Langone Health. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by NYU Langone Health · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Glioma by NYU Langone Health — 3 open to participants now, 5 under way, none of them phase 3. Glioma · NYU Langone Health.

Enrollment
5th of 11
21 · median 20
Started
2025
with 1 other
Phase 1
4 of 12
2 open now
Registered
9th of 12
by date

Among the 12 studies in Glioma by NYU Langone Health, this one is the 5th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2025, is one of 4 in phase 1, and was the 9th registered.

Glioma

1,456 studies on the registry are indexed under Glioma; 351 are open to participants now.

Browse Glioma studies →

Open to participants now

3 of the 12 studies in Glioma by NYU Langone Health are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Glioma by NYU Langone Health, or all of them as a file.
02

Study summary

Single institution study to assess the safety of concurrent Azeliragon with craniospinal irradiation (CSI) in patients with leptomeningeal metastasis from solid tumor malignancies and high-grade gliomas.

03

Conditions studied

  • Solid Tumor
  • High-grade Glioma
  • Leptomeningeal Metastasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with solid tumor or high grade glioma with established radiographically and/or through cerebrospinal fluid (CSF) cytology
  • Patients who are candidates for radiation therapy for the treatment of leptomeningeal metastasis
  • Patients with Performance Status of 60 or greater.
  • Male or non-pregnant and non-lactating female and ≥ 18 years of age.
  • Patients with (ANC) ≥ 1.0 × 109/L, count ≥ 75,000/mm3 (75 × 109/L), and (Hgb) ≥ 8 g/dL. Transfusion or growth factor support is allowed.
  • Patients with (AST) [serum glutamic-oxaloacetic transaminase(SGOT)], alanine aminotransferase (ALT) [serum glutamic-pyruvic transaminase (SGPT)] ≤ 2.5 × (ULN), unless liver are present, then ≤ 5 x ULN is acceptable, total ≤ 1.5 × ULN, and estimated of > 30 mL/min (per Cockroft-Gault formula).
  • Patient has been informed about the nature of the study, and has agreed to participate in the study, and signed the Form (ICF) prior to participation in any study-related activities.

Exclusion criteria

Exclusion Criteria:

  • Patient has a , per investigator assessment, of less than 2 months.
  • Patients unable to complete the English quality of life questionnaires
  • Patient with extensive systemic disease and who declined standard systemic treatment options
  • Patient who is unable to undergo magnetic resonance imaging (MRI) brain and spine with gadolinium contrast
  • Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerance
  • Active, uncontrolled bacterial, or fungal infection(s) requiring systemic therapy.
  • Patient has a concomitant serious medical or psychiatric illness that, in the opinion of the investigator, could compromise the patient's safety or the study data integrity.
  • Patient is unwilling or unable to comply with study procedures, including, but not limited to self-administration of oral medication.
  • Patients with a gastrointestinal condition that could interfere with swallowing or absorption.
  • Females of who are sexually active or males with female partners of childbearing potential, where either the female or the male is unwilling to use a highly effective method of during the trial and for 6 months after the last administration of study drug.
  • Pregnant or lactating women
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Dose Determination followed by Dose Expansion

    Patients with leptomeningeal metastasis from a solid tumor or primary CNS high-grade glioma will be enrolled and start Azeliragon 7 days prior to CSI, during CSI, and for 7 days days after completion of CSI (Dose Determination). Patients will be monitored for dose limiting toxicities during protocol therapy. Once the recommended dose is identified, additional patients will be treated with Azeliragon at recommended dose in combination with craniospinal irradiation (Dose Expansion).

    Drug: Azeliragon · Procedure: CSI

Interventions

  • Azeliragon is orally administered. Patients start Azeliragon 7 days before CSI and take their last dose 7 days post-CSI. The first 6 patients will start at Dose Level 1 \[DL1\] (Loading dose for 7 days: 30 mg twice daily; Concurrent/adjuvant dose: 20 mg once daily). If 1 or fewer of 6 patients develop dose-limiting toxicity (DLT) then the recommended dose will be DL1. If at least 2 of 6 develops a DLT, then an additional 6 patients will be enrolled at Dose Level -1 \[DL-1\] (Loading dose for 7 days: 15mg twice daily; Concurrent/adjuvant dose: 10mg once daily). If 1 or fewer out of 6 patients at DL-1 develop DLT, then the recommended dose will be DL-1. If at least 2 of 6 at DL-1 develops a DLT, then an additional 6 patients will be enrolled at Dose Level -2 \[DL-2\] (Loading dose for 7 days: 15mg twice daily; Concurrent/adjuvant dose: 5mg once daily). At the recommended dose, an additional 14 patients will be enrolled for the Dose Expansion portion.

  • ProcedureCSI

    Patients will receive CSI.

06

What researchers measure

Primary outcomes

  1. Number of Patients with Dose-Limiting Toxicities (DLTs) at Dose Level 1

    DLTs assess using Common Terminology Criteria for Adverse Events (CTCAE) v 5.0.

    Time frame: Up to Week 4

  2. Number of Patients with DLTs at Dose Level -1

    DLTs assess using CTCAE v 5.0.

    Time frame: Up to Week 4

  3. Number of Patients with DLTs at Dose Level -2

    DLTs assess using CTCAE v 5.0.

    Time frame: Up to Week 4

Secondary outcomes

  1. Central nervous system (CNS) progression-free survival (PFS)

    CNS PFS is defined as time from randomization until CNS progression or death, whichever occurs first.

    Time frame: Up to Month 13 (12 Months Post-Protocol Therapy)

  2. Overall Survival (OS)

    OS is defined as time from randomization until death.

    Time frame: Up to Month 13 (12 Months Post-Protocol Therapy)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: Jonathan.Yang@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data upon reasonable request. Requests should be directed to Jonathan.Yang@nyulangone.org. To gain access, data requestors will need to sign a data access agreement. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's DSSB.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jan 2027, 23 months after the start.

Of 166 non-industry phase 1 interventional studies under Glioma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 87. This study's planned 23 months is below that.

Counting every sponsor, half of 213 studies reached it within 59 months; a quarter within 36 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2024
First posted
Dec 9, 2024
StartActual
Feb 18, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2031
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06724926
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Dec 9, 2024
Start date
Feb 18, 2025
Primary completion
Jan 2027 (estimated)
Completion
Jan 2031 (estimated)
Last update
May 18, 2026

Study contacts

Jonathan Yang, MD, PhD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azeliragon

Start the discussion